Table 5.
Metabolites and their pathways which correlate with sleep disruption.
| Significant Metabolites | Significant Pathways | |||
|---|---|---|---|---|
| Metabolite | r | Pathway | Matched Metabolites | Impact |
| Isocitric acid *** | 0.37 | Citrate cycle (TCA cycle) ** | Isocitrate ***, Citrate **, Fumarate * | 0.17 |
| Glucuronic acid *** | 0.36 | Glyoxylate and dicarboxylate metabolism * | Citrate **, Glycine *, Isocitrate *** | 0.14 |
| Citric acid ** | 0.35 | Pentose phosphate pathway * | D-Ribose 5-phosphate **, D-Ribose * | 0.17 |
| Phenylpyruvic acid ** | 0.33 | |||
| 3S-methyl-2-oxo-pentanoic acid ** | 0.32 | |||
| Phenylbutazone ** | −0.32 | |||
| trans-Aconitic acid ** | 0.31 | |||
| 2-Hydroxybutyric acid ** | −0.30 | |||
| Cytidine ** | −0.29 | |||
| Amiloride ** | −0.29 | |||
| D-Ribose 5-phosphate ** | −0.28 | |||
| 4-Hydroxyproline * | 0.27 | |||
| Glycine * | −0.26 | |||
| Citraconic acid * | 0.26 | |||
| D-Ribose * | 0.26 | |||
| Ketoleucine * | 0.26 | |||
| 1-Methylhistamine * | −0.25 | |||
| Dodecanoic acid * | 0.25 | |||
| Pregnenolone sulfate * | −0.25 | |||
| 5-Aminolevulinic acid * | 0.24 | |||
| 2-Methylglutaric acid * | −0.24 | |||
| Taurine * | −0.24 | |||
| L-3-Phenyllactic acid * | 0.24 | |||
| Fumaric acid * | 0.23 | |||
| N-Acetylglutamine * | −0.22 | |||
| Dihydroxyacetone * | −0.22 | |||
* p ≤ 0.05, ** p ≤ 0.01; *** p ≤ 0.001.